References
- Buckle GC, Fischer Walker CL, Black RE. Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J. Global Health 2(1), 010401 (2012).
- Ochiai RL Acosta CJ, Danovaro-Holliday MC et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull. WHO 86(5), 260–268 (2008).
- Reddy EA Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect. Dis. 10(6), 417–432 (2010).
- Jensenius M, Han PV, Schlagenhauf P et al. Acute and potentially life-threatening tropical diseases in western travellers – a GeoSentinel multicentre study, 1996–2011. Am. J. Trop. Med. Hyg. 88(2), 397–404 (2013).
- Butler T, Knight J, Nath SK, Speelman P, Roy SK, Azad MAK. Typhoid fever complicated by intestinal perforation: a persisting fatal disease requiring surgical management. Rev. Infect. Dis. 7(2), 244–256 (1985).
- Hoffman SL Punjabi NH, Kumala S et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high dose dexamethasone. N. Engl. J. Med. 310(2), 82–88 (1984).
- Wain J, Bay PVB Vinh H et al. Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J. Clin. Microbiol. 39(4), 1571–1576 (2001).
- Chau TT Campbell JI, Galindo CM et al. Antimicrobial drug resistance of Salmonella enteric serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob. Agents Chemother. 51(12), 4315–4323 (2007).
- Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. Br. Med. J. 333, 78–82 (2006).
- Effa EE Lassi ZS, Critchley JA et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review). Cochrane Database Syst. Rev. (10), CD004530 (2011).
- Wilcox MH. Chloramphenicol and thiamphenicol. In: Antibiotics and Chemotherapy (8th Edition). Finch RG, Greenwood D, Norrby SR, Whitley RJ (Eds). Churchill Livingstone, Edinburgh, UK, 279–283 (2003).
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing: 23rd Informational Supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 33(1) (2013).
- Rupali P, Abraham OC, Jesudason MV et al. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn. Microbiol. Infect. Dis. 49(1), 1–3 (2004).
- Crump JA Kretsinger K, Gay K et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet multicentre retrospective cohort study. Antimicrob. Agents Chemother. 52(4), 1278–1284 (2008).
- Parry CM Vinh H, Chinh NT et al. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. PLoS Negl. Trop. Dis. 5(6), e1163 (2011).
- Forsythe CT Ernst ME. Do fluoroquinolones commonly cause arthropathy in children? Can. J. Emerg. Med. 9(6), 459–462 (2007).
- Park-Wyllie LY Juurlink DN, Kopp A et al. Outpatient gatifloxacin therapy and dysglycaemia in older adults. N. Engl. J. Med. 354(13), 1352–1361 (2006).
- Cao XTP Kneen R, Nguyen TA et al. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatr. Infect. Dis. J. 18(3), 245–248 (1999).
- Pandit A, Arjyal A, Day JN et al. An open randomised comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS ONE 2(6), e542 (2007).
- Capoor MR Nair D, Posi J et al. Minimum inhibitory concentration (MIC) of carbapenems and tigecycline against Salmonella spp. J. Med. Microbiol. 58(3), 337–341 (2009).
- Caudron JM Ford N, Henkens M, Macé C, Kiddle-Munroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop. Med. Int. Health 13, 1062–1072 (2008).
- Gnanadhas DP Thomas MB, Elango M, Raichur AM, Chakravortty. Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella. J. Antimicrob. Chemother. 68(11), 2576–2586 (2013).